Advertisement

Evaluating niacin in its various forms

  • Robert H Knopp
    Correspondence
    Address for reprints: Robert H. Knopp, MD, 325 Ninth Avenue, Seattle, Washington 98144
    Affiliations
    Division of Metabolism, Endocrinology and Nutrition, Northwest Lipid Research Clinic, University of Washington, Seattle, Washington, USA
    Search for articles by this author

      Abstract

      Niacin is available in a number of different formulations according to the speed of drug release. The nomenclature is not standardized, and many names are used interchangeably, creating confusion. Formulations that differ in time of release may have different lipid effects and vary in their adverse reaction profiles. Studies comparing immediate-release with various time-release formulations illustrate these variations. Studies have found immediate-release and the intermediate, or extended-release, once-a-day, prescription form of niacin (i.e., Niaspan), to be essentially equivalent with respect to their efficacy in reducing triglycerides and increasing high-density lipoprotein cholesterol (HDL-C). However, there are fewer side effects and better compliance associated with the latter form.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Knopp R.H
        Drug treatment of lipid disorders (see comments).
        N Engl J Med. 1999; 341: 498-511
      1. The Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360–381.

        • Brown G
        • Albers J.J
        • Fisher L.D
        • Schaefer S.M
        • Lin J.T
        • Kaplan C
        • Zhao X.Q
        • Bisson B.D
        • Fitzpatrick V.F
        • Dodge H.T
        Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B.
        N Engl J Med. 1990; 323: 1289-1298
        • Knopp R.H
        • Ginsberg J
        • Albers J.J
        • Hoff C
        • Ogilvie J.T
        • Warnick G.R
        • Burrows E
        • Retziaff B
        • Poole M
        Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects.
        Metabolism. 1985; 34: 642-650
        • Schlierf G
        • Dorow E
        Diurnal patterns of triglycerides, free fatty acids, blood sugar, and insulin during carbohydrate-induction in man and their modification by nocturnal suppression of lipolysis.
        J Clin Invest. 1973; 52: 732-740
        • Knopp R.H
        • Alagona P
        • Davidson M
        • Goldberg A.C
        • Kafonek S.D
        • Kashyap M
        • Sprecher D
        • Superko H.R
        • Jenkins S
        • Marcovina S
        Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
        Metabolism. 1998; 47: 1097-1104